Water Street Healthcare Partners has held the first and final close of its sixth private equity fund at US$1.9bn. Fund VI was oversubscribed and closed at its hard cap.
With the newly raised capital, the US-based health care investment firm is looking to invest in mid-market businesses specialising in medical products and diagnostics, pharmaceutical and life sciences, and health care services.
Water Street has completed more than 180 investments and acquisitions to build more than 48 companies.
Companies in Europe currently partnered with Water Street include its 2022 investment in Catalyx, which specialises in global operational processes for highly regulated industries, and Solvias, a global provider of chemistry, manufacturing, and control analytics to the life science industry (in which it invested in 2020), as well as many companies like EVERSANA that are headquartered in North America and expanding their operations in Europe.
